Shenzhen Bioeasy Biotechnology Stock Cash Flow From Operations
| 300942 Stock | 10.55 1.76 20.02% |
Shenzhen Bioeasy Biotechnology fundamentals help investors to digest information that contributes to Shenzhen Bioeasy's financial success or failures. It also enables traders to predict the movement of Shenzhen Stock. The fundamental analysis module provides a way to measure Shenzhen Bioeasy's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shenzhen Bioeasy stock.
Shenzhen | Cash Flow From Operations |
Shenzhen Bioeasy Biotechnology Company Cash Flow From Operations Analysis
Shenzhen Bioeasy's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Shenzhen Bioeasy Cash Flow From Operations | (37.25 M) |
Most of Shenzhen Bioeasy's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shenzhen Bioeasy Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Shenzhen Bioeasy Biotechnology has (37.25 Million) in Cash Flow From Operations. This is 107.06% lower than that of the Biotechnology sector and 159.58% lower than that of the Health Care industry. The cash flow from operations for all China stocks is 103.84% higher than that of the company.
Shenzhen Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shenzhen Bioeasy's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shenzhen Bioeasy could also be used in its relative valuation, which is a method of valuing Shenzhen Bioeasy by comparing valuation metrics of similar companies.Shenzhen Bioeasy is currently under evaluation in cash flow from operations category among its peers.
Shenzhen Fundamentals
| Return On Equity | -0.0919 | ||||
| Return On Asset | -0.0157 | ||||
| Profit Margin | (0.33) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 3.35 B | ||||
| Shares Outstanding | 400.87 M | ||||
| Shares Owned By Insiders | 74.88 % | ||||
| Shares Owned By Institutions | 1.20 % | ||||
| Price To Book | 4.13 X | ||||
| Price To Sales | 17.12 X | ||||
| Revenue | 254.11 M | ||||
| Gross Profit | 428.03 M | ||||
| EBITDA | (16.9 M) | ||||
| Net Income | (184.91 M) | ||||
| Total Debt | 507.61 M | ||||
| Book Value Per Share | 2.13 X | ||||
| Cash Flow From Operations | (37.25 M) | ||||
| Earnings Per Share | (0.20) X | ||||
| Number Of Employees | 389 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 4.23 B | ||||
| Total Asset | 1.36 B | ||||
| Retained Earnings | 138.44 M | ||||
| Working Capital | 600.74 M | ||||
| Net Asset | 1.36 B |
About Shenzhen Bioeasy Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shenzhen Bioeasy Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shenzhen Bioeasy using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shenzhen Bioeasy Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Shenzhen Stock
Shenzhen Bioeasy financial ratios help investors to determine whether Shenzhen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shenzhen with respect to the benefits of owning Shenzhen Bioeasy security.